Amalgamated Bank grew its holdings in Gilead Sciences (NASDAQ:GILD) by 9.6% during the fourth quarter, HoldingsChannel.com reports. The fund owned 169,797 shares of the biopharmaceutical company’s stock after purchasing an additional 14,926 shares during the quarter. Amalgamated Bank’s holdings in Gilead Sciences were worth $12,164,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Welch Investments LLC purchased a new position in shares of Gilead Sciences in the 3rd quarter valued at $108,000. Wealthcare Advisory Partners LLC purchased a new stake in Gilead Sciences during the 3rd quarter worth $133,000. Horan Capital Advisors LLC. purchased a new stake in Gilead Sciences during the 3rd quarter worth $144,000. Hanson & Doremus Investment Management increased its stake in Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 1,613 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Gilead Sciences during the 2nd quarter worth $147,000. 77.91% of the stock is currently owned by institutional investors and hedge funds.
In other news, EVP Gregg H. Alton sold 30,000 shares of Gilead Sciences stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $79.00, for a total value of $2,370,000.00. Following the completion of the transaction, the executive vice president now directly owns 57,114 shares of the company’s stock, valued at approximately $4,512,006. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction dated Monday, April 2nd. The shares were sold at an average price of $73.14, for a total transaction of $3,657,000.00. Following the completion of the transaction, the director now directly owns 3,067,762 shares of the company’s stock, valued at $224,376,112.68. The disclosure for this sale can be found here. Insiders sold a total of 426,934 shares of company stock valued at $33,847,101 over the last ninety days. Company insiders own 1.30% of the company’s stock.
Shares of GILD stock opened at $73.41 on Monday. The firm has a market cap of $95,715.63, a price-to-earnings ratio of 8.58, a P/E/G ratio of -1.69 and a beta of 1.19. The company has a quick ratio of 2.67, a current ratio of 2.74 and a debt-to-equity ratio of 1.53. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $89.54.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The company had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. During the same period last year, the business earned $2.70 EPS. The firm’s revenue for the quarter was down 18.7% compared to the same quarter last year. equities analysts forecast that Gilead Sciences will post 6.21 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, March 29th. Stockholders of record on Friday, March 16th were issued a $0.57 dividend. The ex-dividend date of this dividend was Thursday, March 15th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a dividend yield of 3.11%. Gilead Sciences’s payout ratio is 26.64%.
Several research firms recently issued reports on GILD. Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 price target on the stock in a research note on Monday, February 5th. Leerink Swann dropped their price target on shares of Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 7th. Maxim Group set a $94.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Tuesday, February 6th. Bank of America lifted their price target on shares of Gilead Sciences from $82.00 to $87.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 7th. Finally, Citigroup reaffirmed a “buy” rating and set a $105.00 price target (up previously from $103.00) on shares of Gilead Sciences in a research note on Thursday, February 8th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Gilead Sciences presently has an average rating of “Buy” and an average price target of $88.61.
TRADEMARK VIOLATION NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/09/gilead-sciences-gild-holdings-boosted-by-amalgamated-bank.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.